Photodynamic therapy (PDT) is a minimally-invasive photochemical-based approach that uses a combination of a light-activated drug (photosensitizer, PS) and the light of a specific wavelength to damage the target tumor tissue by generating reactive oxygen species [1]. meta-tetra(hydroxyphenyl)chlorin (mTHPC) is a highly efficient PS, clinically approved and used as a solvent-based formulation (Foscan®, Biolitec Research GmbH, Jena, Germany) for the PDT treatment of head and neck cancers [2]. Low solubility of mTHPC in aqueous solutions represents serious limitation for its application in clinical practice. mTHPC may form large-scale aggregates and precipitates just after injection [3]. It leads to reduced efficacy, induces pain upon administration and prolonged skin photosensitivity. Furthermore, mTHPC demonstrates extremely low rate of distribution between different biological structures. One of the possible ways to enhance the aqueous solubility of drugs is application of cyclodextrins (CDs). CDs are a well-known family of cyclic oligosaccharides with a hydrophobic internal cavity. CDs have already been used as carries for several drugs to improve stability against chemical and photochemical degradation and are suggested to be perspective formulation for introduction of apolar porphyrin during PDT.[4]. It is well known that mechanisms of PS transport in blood play an important role in the control PS biodistribution during PDT. PS localization in different tissues strongly depends on the its binding and distribution of the drug among blood components (serum proteins, blood cells) [5]. The aim of our study was to estimate the influence of methyl-β-cyclodextrin (m-β-CD) on mTHPC biodistribution in blood.
mTHPC provided by Biolitec Research GmbH (Germany). All CDs were from AraChem (Nederland). mTHPC accumulation in blood cells was measured by flow cytometer FC500 (Beckman Coulter).
mTHPC forms readily an inclusion complexes with different types of CDs. We estimated the stoichiometry ratio and apparent constant binding for this process. It was obtained that the values of the apparent constants for the complexes between mTHPC and m-β-CD are very high: $K_{1:1}\approx 1.6\times 10^7~M^{-1}$ for mTHPC: m-β-CD complexes and $K_{1:2}\approx 1.5\times 10^6~M^{-1}$ for mTHPC: 2 m-β-CD complexes.
We have studied aggregation state and distribution among different proteins of mTHPC after its introduction into human serum samples. After introduction mTHPC molecules form aggregates existing in sample for several hours. After 4-6 hours of incubation the most part of mTHPC disaggregates and bounds to serum proteins. By size-exclusion gel chromatography it was shown that in serum mTHPC preferentially (more 95%) bound to lipoproteins. Introduction of m-β-CD into serum sample significantly accelerates the process of mTHPC disaggregation. In the presence of 3×10-5 M m-β-CD mTHPC disaggregation takes only 20 minutes. CD has no influence on mTHPC distribution among different proteins. When m-β-CD concentration is above 3×10-5 M a part of mTHPC molecules redistributes from serum proteins to CDs complexes. This is in accordance with an appearance of new mTHPC peak of chromatography elution curve in the region of high exclusion volumes
We have estimated the effect of CDs on mTHPC distribution between plasma and blood cells. It was obtained that m-β-CD introduction into whole blood has different effects on the mTHPC accumulation by erythrocytes and leukocytes. Only slight increase of mTHPC accumulation is observed in erythrocytes (~1.2 times) while in the case of leukocytes a significant (~3.5 times) growth of intracellular PS accumulation is detected. This acceleration effect is strongly dependent on m-β-CD content in blood. It rises until m-β-CD concentration in blood is less then 2×10-5 M and goes down at higher concentration. When CD content in blood exceeds 2×10-4 M, mTHPC uptake by cells becomes less as compared with control sample.
The data obtained indicate that m-β-CD has different effects on mTHPC distribution in blood and can be used for modification of its pharmacokinetics. We will discuss the role of CD characteristics on kinetic and equilibrium distribution of mTHPC in vasculature and estimate an ability of improving the current PDT treatment protocols with CD.